文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

作者信息

Kim Chul, Prasad Vinay

机构信息

Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland.

出版信息

JAMA Intern Med. 2015 Dec;175(12):1992-4. doi: 10.1001/jamainternmed.2015.5868.

DOI:10.1001/jamainternmed.2015.5868
PMID:26502403
Abstract
摘要

相似文献

[1]
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

JAMA Intern Med. 2015-12

[2]
End points and United States Food and Drug Administration approval of oncology drugs.

J Clin Oncol. 2003-4-1

[3]
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.

J Clin Oncol. 2009-10-13

[4]
Assessing tumor-related signs and symptoms to support cancer drug approval.

J Biopharm Stat. 2004-2

[5]
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.

Int J Technol Assess Health Care. 2019-11-28

[6]
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

JAMA. 2011-6-8

[7]
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.

JAMA Oncol. 2018-11-1

[8]
Meaningful endpoints for therapies approved for hematologic malignancies.

Cancer. 2017-5-15

[9]
Clinically relevant end points and new drug approvals for myeloma.

Leukemia. 2008-2

[10]
The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.

Ann Oncol. 2018-3-1

引用本文的文献

[1]
Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis.

Invest New Drugs. 2025-9-9

[2]
Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis.

BMJ Oncol. 2025-5-6

[3]
Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective.

Nat Rev Clin Oncol. 2025-5

[4]
The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data.

JRSM Open. 2025-2-24

[5]
The Erosion of Healthcare and Scientific Integrity: A Growing Concern.

J Healthc Leadersh. 2025-2-21

[6]
Endpoints for trials of adjuvant anticancer therapies.

BMJ Oncol. 2023-12-21

[7]
Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology.

BMJ Oncol. 2024-7-11

[8]
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.

Nat Med. 2025-3

[9]
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022.

BMC Med. 2024-12-18

[10]
Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.

Cancer Med. 2024-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索